Company intelligence / Profile preview

ERX Pharmaceuticals

Cambridge, Massachusetts, USAerxpharmaceuticals.com ↗

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

ERX-1000, the company's lead drug candidate, has completed a Phase 1 double-blind, placebo-controlled, single and multiple oral dose study in healthy obese and non-obese subjects. In preclinical studies, ERX-1000 showed a 45% reduction in body weight in diet-induced severely obese mice.

Therapeutic areas: EndocrinologyRare DiseasesMetabolic Disorders
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

2 assets

ERX1000

1 more asset in the full pipeline.

Request access →

Partnerships

Boston Children's Hospital

Beyond the preview

Go deeper on ERX Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ERX Pharmaceuticals.

Explore the full profile